Group 1 - The company, Mayinglong Pharmaceutical (600993.SH), announced that its subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., has received the drug registration certificate for Olopatadine Hydrochloride Eye Drops from the National Medical Products Administration [1] - The approved drug is indicated for the treatment of allergic conjunctivitis-related eye itching [1]

Core Viewpoint - The company announced that its subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., has received the drug registration certificate for Olopatadine Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant step in expanding its product offerings in the ophthalmic market [1] Group 1 - The approved product, Olopatadine Hydrochloride Eye Drops, is intended for the treatment of allergic conjunctivitis-related eye itching [1]

通过天眼查大数据分析，马应龙药业集团股份有限公司共对外投资了30家企业，参与招投标项目5000 次，知识产权方面有商标信息543条，专利信息212条，此外企业还拥有行政许可329个。 来源：金融界 马应龙最新一期业绩显示，截至2025一季报，公司营业总收入9.69亿元、同比增长1.48%，归属净利润 2.04亿元，同比增长2.99%，扣非净利润1.95亿元，同比增长1.01%，流动比率4.601、速动比率4.287、 资产负债率19.03%。 天眼查商业履历信息显示，马应龙药业集团股份有限公司，成立于1994年，位于武汉市，是一家以从事 医药制造业为主的企业。企业注册资本43105.3891万人民币，实缴资本14818.2036万人民币。公司法定 代表人为陈平。 金融界消息 截至2025年8月14日收盘，马应龙（600993）报收于27.53元，下跌0.58%，换手率1.74%， 成交量7.47万手，成交金额2.06亿元。 资金流向方面，今日主力资金净流入2051.85万元，占比成交额9.94%。其中，超大单净流出1615.49万 元、占成交额7.83%，大单净流入3667.34万元、占成交额17.77%，中 ...

Group 1 - The stock price of XD Mayinglong (600993) closed at 27.9 yuan, down 1.03% with a turnover rate of 1.05% and a trading volume of 45,000 hands, amounting to 126 million yuan [1] - The latest financial report for Mayinglong shows total operating revenue of 969 million yuan, a year-on-year increase of 1.48%, and a net profit attributable to shareholders of 204 million yuan, up 2.99% year-on-year [1] - The company has a current ratio of 4.601, a quick ratio of 4.287, and a debt-to-asset ratio of 19.03% [1] Group 2 - Mayinglong has made investments in 30 companies and participated in 5,000 bidding projects [2] - The company holds 543 trademark registrations and 212 patents, along with 327 administrative licenses [2]

证券之星消息，8月5日，马应龙（600993）融资买入2127.22万元，融资偿还1889.05万元，融资净买入 238.17万元，融资余额2.52亿元，近3个交易日已连续净买入累计1414.21万元，近20个交易日中有12个 交易日出现融资净买入。 融资融券余额2.54亿元，较昨日上涨1.0%。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-05 | 2.54亿 | 252.55万 | 1.00% | | 2025-08-04 | 2.52亿 | 676.89万 | 2.76% | | 2025-08-01 | 2.45亿 | 533.93万 | 2.23% | | 2025-07-31 | 2.40亿 | -198.14万 | -0.82% | | 2025-07-30 | 2.42亿 | -551.73万 | -2.23% | 小知识 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-05 | 238.17万 | ...

Group 1 - The core point of the announcement is that China Baoan Group has successfully lifted the pledge on 50,000,000 shares of Ma Yinglong Pharmaceutical Group, maintaining its credit limit with China Merchants Bank unchanged [1][2] - After the release of the pledge, China Baoan holds a total of 126,163,313 shares of Ma Yinglong, which accounts for 29.27% of Ma Yinglong's total share capital [1] - Following this announcement, there are no pledged shares remaining for China Baoan in relation to its holdings in Ma Yinglong [1]

Group 1 - The controlling shareholder, China Baoan, holds a total of 126,163,313 shares in the company, accounting for 29.27% of the total share capital [2] - China Baoan has released the pledge on 50,000,000 shares, and after this release, there are no pledged shares remaining [2] - The release of the pledge was completed on August 4, 2025, through the China Securities Depository and Clearing Corporation Limited and China Merchants Bank Shenzhen Branch [2] Group 2 - There are currently no plans for subsequent pledges of the released shares, and the company will fulfill its information disclosure obligations if there are any changes [2]

证券代码：600993 证券简称：马应龙 公告编号：临 2025-018 重要内容提示: ? 公司控股股东中国宝安持有本公司股份总数 126,163,313 股，占本公司总 股本的 29.27%，本次解除质押 50,000,000 股，解除质押后，中国宝安所持有的 本公司股份不存在被质押的情况。 公司"）接控股股东中国宝安集团股份有限公司（以下简称"中国宝安"）函告， 限公司深圳分行办理了本公司 50,000,000 股无限售流通股解除质押手续，具体情 况如下： | 股东名称 中国宝安集团股份有限公司 | | | | | | --- | --- | --- | --- | --- | | 本次解除质押股份（股） 50,000,000 | | | | | | 占其所持股份比例（%） 39.63 | | | | | | 11.60 占公司总股本比例（%） | | | | | | 解除质押时间 2025 月 4 | 年 | 8 | 日 | | | 126,163,313 持股数量（股） | | | | | | 持股比例（%） 29.27 | | | | | | 剩余被质押股份数量（股） 0 | | | | | | ...

Core Viewpoint - On August 5, 2025, the company announced that its controlling shareholder, China Baoan Group Co., Ltd., completed the release of pledge for 50,000,000 unrestricted circulating shares on August 4, 2025 [1] Summary by Relevant Sections - Announcement Date: The announcement was made on the evening of August 5, 2025 [1] - Shareholder Action: China Baoan completed the release of pledge for 50 million shares [1] - Financial Institutions Involved: The transaction was processed through China Securities Depository and Clearing Corporation Limited and Shenzhen Branch of China Merchants Bank [1]

马应龙（SH 600993，收盘价：29.33元）8月5日晚间发布公告称，公司控股股东中国宝安持有公司股份 总数约1.26亿股，占公司总股本的29.27%，本次解除质押5000万股，解除质押后，中国宝安所持有的公 司股份不存在被质押的情况。 2024年1至12月份，马应龙的营业收入构成为：医药工业占比57.98%，医药商业占比33.5%，医院诊疗 占比12.04%，其他业务占比1.3%，内部抵销占比-4.81%。 （文章来源：每日经济新闻） ...